Table 5 Clinical features of six Japanese patients with drug-induced lung disease due to olaparib
Case | Year of publication | Author | Age/Sex | Primary disease | Olaparib dose (mg/day) | Olaparib oral durations | Symptoms | Oxygenation | CT findings | Treatment method | Effect of treatment | Re-administer olaparib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 2020 | Sakai et al. | 61/F | peritoneal cancer | 600 | 4 months | fever, hemosputum, fatigue | PaO2 67.2 Torr (room air) | non-cardiogenic pulmonary edema pattern | withdrawal of Olaparib | improvement | re-administered without relapse |
2 | 2020 | Sakai et al. | 53/F | ovarian cancer | 600 | 2 months | fever | SpO2 98%(room air) | HP-like pattern | withdrawal of Olaparib | improvement | re-administered without relapse |
3 | 2020 | Suzuki et al. | 34/F | breast cancer | 600 | 7 weeks | fever, cough, sputum | SpO2 97%(room air) | faint ground glass shadow | withdrawal of Olaparib and PSL 1mg/kg | improvement | not done |
4 | 2022 | Presentcase 1 | 72/F | ovarian cancer | 600 | 4 months | fever, fatigue | PaO2 73.7 Torr (room air) | HP-like pattern | withdrawal of Olaparib and PSL 0.6 mg/kg | improvement | not done |
5 | 2022 | Presentcase 2 | 51/F | ovarian cancer | 600 | 8 months | fever, fatigue | SpO2 99%(room air) | HP-like pattern | withdrawal of Olaparib | improvement | not done |
6 | 2022 | Presentcase 3 | 78/F | ovarian cancer | 600 | 3 weeks | cough, dyspnea on effort | PaO2 74.7 Torr (FiO2 0.5) | NSIP and OP pattern | withdrawal of Olaparib and mPSL pulse therapy | improvement | not done |